Obermatt
See Similar Stocks →

ANI Pharma

NMQ:ANIP · US00182C1036
PharmaceuticalsMedium

360

98
EV / EBIT73
Price / Owner Earnings49
Owner Earnings Yield84
Dividend Yield1
Price/Sales87
EV / Gross Profit67
Price/Book47
Return on Capital65
Cash Return on Capital88
Return on Equity86
EBIT Margin52
Gross Profitability73
Cash Conversion67
Accruals69
Owner Earnings Margin72
Sales growth75
Profit Growth84
Long-Term EPS Growth54
Owner Earnings Growth88
Reinvestment26
Price momentum67
Debt load23
Refinancing96
Debt Payback42
Liquidity71
Analyst ratings37
Opinion Changes50
Price Target Upside28
Market mood37
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

ANI Pharma generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeNASDAQGM
Founded2001
Employees495
Websiteanipharmaceuticals.com
ISINUS00182C1036
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
OphthalmologyNephrologyChronic DiseasesPain ManagementInflammationPulmonologyDiabetesBiotechnologyHealth CareManufacturingPharmaceutical

Description

ANI Pharmaceuticals, Inc. (ANI Pharmaceuticals) operates as a diversified bio-pharmaceutical company. On September 16, 2024, the company acquired Alimera Sciences, Inc. (‘Alimera’). In connection with the acquisition, the company added two new produ…

Analysis

Quality compounder

ANI Pharmaceuticals, Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth.

The price is attractive. You pay 10.5× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is solid and the balance sheet is adequate. The company scores 20/20 on our value-creation score: strong value creator.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
93
2023202420252026

All-time high

93

Jun 2026

All-time low

60

Jan 2023

Average rank

85

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
87
55
44
56
Price/Earnings
35
70
68
87
Price/Book
47
42
39
46
Dividend Yield
1
1
1
1
Value (overall)
62
53
42
61

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare ANI Pharma with its peers
Amphastar Pharmaceuticals
NSQ:AMPH
63
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Trevi Therapeutics
NMQ:TRVI
96
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
EyePoint
NMQ:EYPT
34
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Supernus Pharma
NMQ:SUPN
81
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Phathom Pharmaceuticals
NSQ:PHAT
37
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ventyx Biosciences
NSQ:VTYX
51
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →